GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » Cyclically Adjusted PS Ratio

Invitae (Invitae) Cyclically Adjusted PS Ratio : 0.00 (As of May. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Invitae Cyclically Adjusted PS Ratio?

As of today (2024-05-04), Invitae's current share price is $0.0035. Invitae's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $1.73. Invitae's Cyclically Adjusted PS Ratio for today is 0.00.

The historical rank and industry rank for Invitae's Cyclically Adjusted PS Ratio or its related term are showing as below:

During the past years, Invitae's highest Cyclically Adjusted PS Ratio was 0.91. The lowest was 0.01. And the median was 0.39.

NVTAQ's Cyclically Adjusted PS Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.335
* Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Invitae's adjusted revenue per share data for the three months ended in Sep. 2023 was $0.440. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.73 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Invitae Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Invitae's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae Cyclically Adjusted PS Ratio Chart

Invitae Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Invitae Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.80 0.66 0.35

Competitive Comparison of Invitae's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Invitae's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitae's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitae's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Invitae's Cyclically Adjusted PS Ratio falls into.



Invitae Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Invitae's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.0035/1.73
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invitae's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Invitae's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.44/129.8595*129.8595
=0.440

Current CPI (Sep. 2023) = 129.8595.

Invitae Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.006 98.326 0.008
201403 0.008 99.695 0.010
201406 0.020 100.560 0.026
201409 0.021 100.428 0.027
201412 0.029 99.070 0.038
201503 0.072 99.621 0.094
201506 0.057 100.684 0.074
201509 0.069 100.392 0.089
201512 0.099 99.792 0.129
201603 0.124 100.470 0.160
201606 0.174 101.688 0.222
201609 0.194 101.861 0.247
201612 0.255 101.863 0.325
201703 0.244 102.862 0.308
201706 0.332 103.349 0.417
201709 0.376 104.136 0.469
201712 0.487 104.011 0.608
201803 0.509 105.290 0.628
201806 0.550 106.317 0.672
201809 0.533 106.507 0.650
201812 0.603 105.998 0.739
201903 0.511 107.251 0.619
201906 0.589 108.070 0.708
201909 0.591 108.329 0.708
201912 0.680 108.420 0.814
202003 0.645 108.902 0.769
202006 0.358 108.767 0.427
202009 0.519 109.815 0.614
202012 0.557 109.897 0.658
202103 0.534 111.754 0.621
202106 0.439 114.631 0.497
202109 0.524 115.734 0.588
202112 0.556 117.630 0.614
202203 0.541 121.301 0.579
202206 0.589 125.017 0.612
202209 0.561 125.227 0.582
202212 0.502 125.222 0.521
202303 0.470 127.348 0.479
202306 0.457 128.729 0.461
202309 0.440 129.860 0.440

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Invitae  (OTCPK:NVTAQ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Invitae Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Invitae's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Invitae (Invitae) Business Description

Traded in Other Exchanges
Address
1400 16th Street, San Francisco, CA, USA, 94103
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
Executives
Ana J. Schrank officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley officer: Chief Commercial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey officer: See Remarks 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons officer: See remarks 2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum officer: Chief Medical Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida officer: General Counsel 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight officer: Chief Operating Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne director 1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George director, officer: CEO 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer officer: Chief Financial Officer 1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland officer: Chief Commercial Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse director 3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers director, other: President, Oncology C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301

Invitae (Invitae) Headlines

From GuruFocus

Q4 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2023 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2020 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Invitae Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 02-14-2024

Q1 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Invitae Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 02-14-2024

Q4 2020 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024